The FDA has granted Tisch MS Research Center of New York investigational new drug approval to launch a Phase I study to test the use of neural stem cells derived from a patient's own bone marrow to treat multiple sclerosis. "To my knowledge, this is the first FDA-approved stem cell trial in the U.S. to investigate direct injection of stem cells into the cerebrospinal fluid of MS patients, and represents an exciting advance in MS research and treatment," lead researcher Dr. Saud Sadiq said.

Related Summaries